A
Overview
Access Vascular develops vascular access devices to reduce complications from IV therapy. Its HydroPICC and HydroMID use the MIMIX biomaterial, a hydrophilic polymer that is designed to minimize the body's foreign body response and clotting on catheter surfaces, without coatings. The products are FDA-cleared, sold to hospitals and clinics, and have shown up to 97% less thrombus formation than conventional catheters in preclinical tests. The goal is to improve patient outcomes, extend catheter life, reduce replacements, and lower healthcare costs for healthcare systems.
Work here?Claim your company